Mostrando 5 resultados de: 5
Filtros aplicados
Subtipo de publicación
Article(5)
Publisher
Canadian Journal of Kidney Health and Disease(1)
European Heart Journal - Cardiovascular Pharmacotherapy(1)
European Heart Journal - Quality of Care and Clinical Outcomes(1)
New England Journal of Medicine(1)
Trials(1)
Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial
ArticleAbstract: Background: Most patients who take antihypertensive medications continue taking them on the morningPalabras claves:acute kidney injury, antihypertensive medication, Hypotension, mean arterial pressure, noncardiac surgeryAutores:Aguado H.J., Amir M., Belley-Cote E.P., Bhatt K., Biccard B.M., Borges F.K., Chan M.T.V., Conen D., Cuerden M., Devereaux P.J., Duceppe E., Efremov S., Eikelboom J.W., Fleischmann E., Garg A.X., Giovanni L., Gross P.L., Jayaram R., Kirov M., Kleinlugtenbelt Y.V., Kurz A., Lamy A., Leslie K., Likhvantsev V.V., Lomivorotov V.V., Ma José Martínez Zapata, Marcucci M., McGillion M.H., McIntyre W., Meyhoff C.S., Ofori S.N., Painter T.W., Paniagua P., Parikh C., Parlow J.L., Patel A., Polanczyk C.A., Richards T., Roshanov P.S., Schmartz D., Sessler D.I., Short T.G., Sontrop J.M., Spence J., Srinathan S., Stillo D., Szczeklik W., Tandon V., Torres D., Van Helder T., Vincent J., Wang C.Y., Wang M.K., Whitlock R.P., Wittmann M., Xavier D.Fuentes:scopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusTranexamic Acid in Patients Undergoing Noncardiac Surgery
ArticleAbstract: Perioperative bleeding is common in patients undergoing noncardiac surgery. Tranexamic acid is an anPalabras claves:Autores:Aguado H.J., Alfonsi P., Amir M., Astrakov S.V., Balasubramanian K., Bangdiwala S.I., Belley-Cote E.P., Bhatt K., Borges F.K., Cafaro T., Chan M.T.V., Conen D., Copland I., de Nadal M., Devereaux P.J., Duceppe E., Efremov S., Eikelboom J.W., Fleischmann E., Garg A.X., Gross P.L., Guyatt G.H., Kleinlugtenbelt Y.V., Lamy A., Landoni G., Leslie K., Likhvantsev V.V., Lomivorotov V.V., Ma José Martínez Zapata, Marcucci M., McGillion M.H., McIntyre W., Meyhoff C.S., Ofori S.N., Painter T.W., Paniagua P., Parlow J.L., Patel A., Polanczyk C.A., Prystajecky M., Rao M., Richards T., Roshanov P.S., Ruetzler K., Schmartz D., Sessler D.I., Short T.G., Spence J., Stillo D., Szczeklik W., Tandon V., Torres D., Turan A., VanHelder T., Vincent J., Wang C.Y., Wang M.K., Whitlock R.P., Wittmann M., Wu W.K.K., Xavier D., Yusuf S.Fuentes:scopusRationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery
ArticleAbstract: Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and asPalabras claves:Cardiovascular Complications, noncardiac surgery, Perioperative bleeding, Perioperative hypotension, Randomized controlled trial, Tranexamic acidAutores:Abubakirov M., Aguado H.J., Alfonsi P., Amir M., Astrakov S.V., Ayad S., Balasubramanian K., Bangdiwala S.I., Belley-Cote E.P., Bhatt K., Biccard B.M., Borges F.K., Chan M.T.V., Cheong C.C., Conen D., Copland I., de Nadal M., Devereaux P.J., Duceppe E., Efremov S., Eikelboom J.W., Fleischmann E., Garg A.X., Gross P.L., Guyatt G.H., Iglesisas P.P., Jayaram R., Kirov M., Kleinlugtenbelt Y.V., Kurz A., Lamy A., Landoni G., Leslie K., Likhvantsev V.V., Lomivorotov V.V., Ma José Martínez Zapata, Marcucci M., McGillion M.H., McIntyre W., Meyhoff C.S., Ofori S.N., Painter T.W., Parlow J.L., Patel A., Petit S., Polanczyk C.A., Rao M., Richards T., Roshanov P.S., Ruetzler K., Schmartz D., Sessler D.I., Short T.G., Spence J., Srinathan S., Stillo D., Szczeklik W., Tandon V., Torres D., VanHelder T., Vincent J., Wang C.Y., Wang M.K., Whitlock R.P., Wittmann M., Wu W.K.K., Xavier D., Yusuf S.Fuentes:scopusThe cost implications of a polypill for primary prevention in the TIPS-3 trial
ArticleAbstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesPalabras claves:Cardiovascular disease, cost analysis, Polypill, Primary PreventionAutores:Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.Fuentes:googlescopus